DE602006018590D1 - Heteroarylharnstoffderivate zur hemmung von chk1 - Google Patents

Heteroarylharnstoffderivate zur hemmung von chk1

Info

Publication number
DE602006018590D1
DE602006018590D1 DE602006018590T DE602006018590T DE602006018590D1 DE 602006018590 D1 DE602006018590 D1 DE 602006018590D1 DE 602006018590 T DE602006018590 T DE 602006018590T DE 602006018590 T DE602006018590 T DE 602006018590T DE 602006018590 D1 DE602006018590 D1 DE 602006018590D1
Authority
DE
Germany
Prior art keywords
heteroaryl
drug derivatives
inhibiting chk1
chk1
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602006018590T
Other languages
German (de)
English (en)
Inventor
Frank Diaz
Francine S Farouz
Ryan Holcomb
Edward A Kesicki
Hua Chee Ooi
Alexander Rudolph
Frank Stappenbeck
Eugene Thorsett
John Joseph Gaudino
Kimba L Fisher
Adam Wade Cook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icos Corp
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Publication of DE602006018590D1 publication Critical patent/DE602006018590D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
DE602006018590T 2005-03-29 2006-03-29 Heteroarylharnstoffderivate zur hemmung von chk1 Expired - Lifetime DE602006018590D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66602605P 2005-03-29 2005-03-29
PCT/US2006/011584 WO2006105262A1 (en) 2005-03-29 2006-03-29 HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHKl

Publications (1)

Publication Number Publication Date
DE602006018590D1 true DE602006018590D1 (de) 2011-01-13

Family

ID=36677174

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006018590T Expired - Lifetime DE602006018590D1 (de) 2005-03-29 2006-03-29 Heteroarylharnstoffderivate zur hemmung von chk1

Country Status (31)

Country Link
US (1) US8093244B2 (https=)
EP (2) EP1869020B1 (https=)
JP (2) JP5117374B2 (https=)
KR (2) KR100912998B1 (https=)
CN (2) CN101151259B (https=)
AR (1) AR056645A1 (https=)
AT (1) ATE490248T1 (https=)
AU (1) AU2006230337B2 (https=)
BR (1) BRPI0609667A2 (https=)
CA (1) CA2602199C (https=)
CR (1) CR9395A (https=)
CY (1) CY1111240T1 (https=)
DE (1) DE602006018590D1 (https=)
DK (1) DK1869020T3 (https=)
EA (1) EA011287B1 (https=)
ES (1) ES2356068T3 (https=)
HR (1) HRP20100678T1 (https=)
IL (1) IL185481A0 (https=)
MA (1) MA29439B1 (https=)
MX (1) MX2007012116A (https=)
NO (1) NO20074944L (https=)
NZ (1) NZ561458A (https=)
PL (1) PL1869020T3 (https=)
PT (1) PT1869020E (https=)
RS (1) RS51616B (https=)
SI (1) SI1869020T1 (https=)
TN (1) TNSN07369A1 (https=)
TW (1) TWI375559B (https=)
UA (1) UA92164C2 (https=)
WO (1) WO2006105262A1 (https=)
ZA (1) ZA200707715B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221367A (en) 1988-08-03 1993-06-22 International Business Machines, Corp. Strained defect-free epitaxial mismatched heterostructures and method of fabrication
MY150649A (en) * 2006-10-20 2014-02-14 Icos Corp Compositions of chk1 inhibitors
CN101200429B (zh) * 2006-12-13 2012-08-22 上海睿智化学研究有限公司 2-硝基-4,5-二卤代苯酚类和2-氨基-4,5-二卤代苯酚类及其盐及其合成方法
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
LT3157566T (lt) 2014-06-17 2019-08-12 Vertex Pharmaceuticals Incorporated Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
HK1258570A1 (zh) 2015-09-30 2019-11-15 Vertex Pharmaceuticals Inc. 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
HRP20220351T1 (hr) 2016-02-04 2022-05-13 Pharmaengine, Inc. 3,5-disupstituirani pirazoli korisni kao inhibitori kinaze 1 kontrolne točke (chk1), i njihove pripreme i primjene
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
US20200108074A1 (en) * 2017-03-31 2020-04-09 Seattle Genetics, Inc. Combinations of chk1- and wee1- inhibitors
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN112457306A (zh) 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
US12404332B2 (en) * 2020-03-13 2025-09-02 Research Development Foundation Methods for diagnosing and treating cancers

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293552A (en) 1978-02-27 1981-10-06 Eli Lilly And Company Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas
US6174993B1 (en) 1997-05-21 2001-01-16 The Children's Medical Center Corp. Short peptides which selectively modulate the activity of serine/threonine kinases
US6218109B1 (en) 1997-09-05 2001-04-17 Baylor College Of Medicine Mammalian checkpoint genes and proteins
GB9718952D0 (en) 1997-09-05 1997-11-12 Medical Res Council Mammalian chk1 effector cell cycle checkpoint protein kinase materials and methods
JP2001518501A (ja) 1997-10-06 2001-10-16 ビーエーエスエフ アクチェンゲゼルシャフト インデノ[1,2−c]−、ナフト[1,2−c]−およびベンゾ[6,7]シクロへプタ[1,2−c]ピラゾール誘導体
EP1135135A4 (en) 1998-09-18 2006-08-09 Smithkline Beecham Corp CHK1 KINASE INHIBITORS
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
WO2001057206A2 (en) 2000-02-03 2001-08-09 Ribozyme Pharmaceuticals, Inc. Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme
AU2001243226A1 (en) 2000-02-25 2001-09-03 The Regents Of The University Of California Scytonemin and methods of using thereof
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
US6534691B2 (en) 2000-07-18 2003-03-18 E. I. Du Pont De Nemours And Company Manufacturing process for α-olefins
ATE295354T1 (de) 2000-08-18 2005-05-15 Agouron Pharma Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen
CA2434066A1 (en) 2001-01-26 2002-09-12 Pharmacia Italia S.P.A. Chromane derivatives, process for their preparation and their use as antitumor agents
UA76977C2 (en) * 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
US7064215B2 (en) 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
WO2003029241A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2003028731A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
DE60229975D1 (de) 2001-10-04 2009-01-02 Smithkline Beecham Corp Nf-kb-inhibitoren
AU2002356871A1 (en) 2001-10-30 2003-05-12 Pharmacia Corporation Heteroaromatic carboxamide derivatives for the treatment of inflammation
US20030119839A1 (en) 2001-12-13 2003-06-26 Nan-Horng Lin Protein kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
EP1501831A1 (en) 2002-04-26 2005-02-02 Warner-Lambert Company Llc Inhibitors of checkpoint kinases (wee1 and chk1)
US7202244B2 (en) * 2002-05-29 2007-04-10 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
US20040034038A1 (en) 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
US7056925B2 (en) * 2002-08-13 2006-06-06 Abbott Laboratories Urea kinase inhibitors
CA2496164C (en) 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
BR0316680A (pt) 2002-11-28 2005-10-18 Schering Ag Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
CA2512683C (en) 2003-01-09 2010-03-16 Pfizer Inc. Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy
EP1765808A1 (en) * 2004-06-25 2007-03-28 ICOS Corporation Bisarylurea derivatives useful for inhibiting chk1
CA2679908A1 (en) 2009-09-23 2011-03-23 Shell Internationale Research Maatschappij B.V. Closed loop solvent extraction process for oil sands
CN104407475B (zh) 2014-12-04 2017-04-05 厦门天马微电子有限公司 液晶显示面板

Also Published As

Publication number Publication date
JP2008535830A (ja) 2008-09-04
EP2330105A1 (en) 2011-06-08
US8093244B2 (en) 2012-01-10
RS51616B (sr) 2011-08-31
EA011287B1 (ru) 2009-02-27
MX2007012116A (es) 2008-04-08
HK1119670A1 (en) 2009-03-13
TW200722090A (en) 2007-06-16
US20090143357A1 (en) 2009-06-04
TWI375559B (en) 2012-11-01
EA200702094A1 (ru) 2008-02-28
UA92164C2 (ru) 2010-10-11
IL185481A0 (en) 2008-01-06
CY1111240T1 (el) 2015-06-11
PL1869020T3 (pl) 2011-05-31
CR9395A (es) 2008-03-31
AU2006230337B2 (en) 2011-10-27
JP5117374B2 (ja) 2013-01-16
HRP20100678T1 (hr) 2011-02-28
NZ561458A (en) 2011-03-31
KR20090031459A (ko) 2009-03-25
AU2006230337A1 (en) 2006-10-05
NO20074944L (no) 2007-10-24
CN101151259A (zh) 2008-03-26
CA2602199C (en) 2013-09-10
KR100912998B1 (ko) 2009-08-20
CN101151259B (zh) 2011-06-15
MA29439B1 (fr) 2008-05-02
SI1869020T1 (sl) 2011-02-28
KR20070107178A (ko) 2007-11-06
WO2006105262A1 (en) 2006-10-05
AR056645A1 (es) 2007-10-17
DK1869020T3 (da) 2011-01-24
ATE490248T1 (de) 2010-12-15
BRPI0609667A2 (pt) 2010-04-20
CN102219784A (zh) 2011-10-19
ES2356068T3 (es) 2011-04-04
TNSN07369A1 (en) 2008-12-31
EP1869020B1 (en) 2010-12-01
EP1869020A1 (en) 2007-12-26
ZA200707715B (en) 2009-09-30
PT1869020E (pt) 2010-12-23
CA2602199A1 (en) 2006-10-05
JP2009227682A (ja) 2009-10-08

Similar Documents

Publication Publication Date Title
DE602007006324D1 (de) Insektizide n-substituierte (heteroaryl) cycloalkylsulfoximine
DK2041139T3 (da) Farmaceutiske forbindelser
BRPI0719991A2 (pt) Derivados de di-hidropiridina úteis como inibidores de proteína cinase
NO20073482L (no) Fremgangsmåte til å stabilisere antidement medikament
CY2014011I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
HUS1400051I1 (hu) Lurazidont tartalmazó gyógyászati készítmény
NO20082223L (no) Fremgangsmåte for inhibering av FLT3-kinase
BRPI0716477A2 (pt) Derivados heteroarila como inibidores de quinase protéica
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
ATE440837T1 (de) Indazol-heteroaryl-derivate
IL185481A0 (en) Heteroaryl urea derivatives useful for inhibiting chk1
DK1957073T3 (da) Lægemiddel
DE602007001593D1 (de) Aryl-/alkylvinylsulfon-hyaluronsäurederivate
DK1937650T3 (da) Heterocykliske forbindelser
SI1942967T1 (sl) Postopek za odmerjanje zdravil
ATE449080T1 (de) 4-phenyl-6-substituierte pyrimidin-2- carbonitrilderivate
ATE487718T1 (de) Substituierte bizyklische pyrimidonderivate
DK1757293T3 (da) Bh4-responsiv hyperphenylalaninæmi-medikamenter
DE602007012260D1 (de) Nitratester von piperidinen
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
DK1910325T3 (da) Nye farmaceutisk forbindelser
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
EP1961750A4 (en) VLA-4-INHIBITORY DRUG
DK1971588T3 (da) Tiglien-3-onderivater

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN